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Appendix Figures
Appendix Figure S1 . A) Non-compartmental analysis of single dose AR-42 pharmacokinetics in mouse. Parameters were derived as outlined in the Materials and Methods section. B) AR-42 dose-response. Starting six days after C-26 cell injection, animals received vehicle or AR-42 orally at 1 (n=8), 3 (n=8), 10 (n=13) or 20 mg/kg (n=6) daily or 50 mg/kg (n=5) every other day for 13 days. Individual animal gastrocnemius weights are presented as a percentage of tumor-free control muscle weight. Dashed reference line (100%) represents the mean tumor-free gastrocnemius mass, solid line represents non-linear fit of dose-response data. C) AR-42's in vitro human HDAC isoform inhibition profile. HDAC activity of recombinant human HDAC enzymes was determined in the presence of 1 μM AR-42 as outlined in the Materials and Methods.
Appendix Figure S2 . Study 1 (male; n=20) and Study 3 (female; n=43) C-26 tumor volumes. Terminal tumor volume comparisons between Study 1 and Study 3. Statistics: ns, no significant between-study differences in tumor volumes. Student's t-test of combined tumor volumes (Study 1 versus Study 3). ns, no significant differences among treatment groups within each study, one-way ANOVA followed by Tukey's multiple comparison test. Individual p-values displayed in tables.
Appendix Figure S3 . Study 4, tumor-bearing male mice receiving AR-42 (10 mg/kg, oral gavage; n=9), TFM-4AS-1 (10 mg/kg, subcutaneous; n=10), Combination of AR-42 and DHT (10 mg/kg oral gavage and 3 mg/kg subcutaneous, respectively; n=10), Combination of AR-42 and TFM-4AS-1 (10 mg/kg, both, n=9) or Vehicle (n=6) and tumor-free mice receiving vehicle (n=6) were treated daily for 12 days starting 6 days post-injection of C-26 cells. A) Tumor volume comparisons between Day 8 and Day 16 post-C-26 cell injection. Statistics: Individual p-values displayed in tables; ns, no significant differences; one-way ANOVA followed by Tukey's multiple comparison test. B) Androgen receptor western blot of C-26 and LLC tumor tissue and associated source cells. Mouse prostate tissue was analyzed as a positive control. C) C-26 cell viability was determined after 48 hours of treatment with DHT or GTx-024 at concentrations of up to 10 µM. Data in panels A and C are presented as means ± SD.
Appendix Figure S4 . Study 4, Terminal epididymal fat pad mass from mice in Study 4 treated as described in Appendix Figure S7 . Statistics: V, T, A indicate statistically significant differences versus tumorbearing vehicle-treated, tumor-bearing TFM-4AS-1-treated and tumor-bearing AR-42-treated groups, respectively. Individual p-values displayed in tables, one-way ANOVA followed by Tukey's multiple comparison test. Data are presented as means ± SD.
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Appendix Figure S5 . Western blot analysis of AR in gastrocnemius muscles from representative mice in Study 1. Black circle -tumor-free, blue square -tumor-free/GTx-024, black triangle -tumor-bearing, blue diamond -tumor/GTx-024, red triangle -tumor/AR-42, green circle -tumor/combo. Appendix Figure S6 . A) Genes differentially regulated in gastrocnemius muscle by 50 mg/kg AR-42 treatment relative to C-26 tumor-bearing vehicle-treated controls from Tseng et al. intersected with genes differentially regulated in quadriceps muscle from both severe and moderately wasting C-26 tumor-bearing mice relative to tumor-free controls from Bonetto et al. B) Canonical pathway analysis using GSEA of the 147 overlapping genes from A. Appendix Figure S7 . Western blot analysis of phospho(p)STAT3 in gastrocnemius muscles from representative mice treated in Study 1. This data is a replicate blot generated from the samples used in Figure 6B . tSTAT3, total STAT3.
Appendix Figure S8.
Principle Component Analysis plots of Study 1 RNA-seq samples utilized for subsequent analyses.
Appendix Figure S9 .
Standard volcano plots from RNA-seq analyses of Study 1 gastrocnemius muscles showing A)
DEGs for tumor-bearing (cachectic) GTx-024-treated (Cx+GTx-024) mice versus tumor-free controls (colored red), and B) DEGs for tumor-bearing AR-42-treated (Cx+AR-42) mice versus tumor-free controls (colored red). Log2-transformed fold change (FC) in expression is plotted on the x-axis and -log10 transformed Benjamini-Hochburg adjusted p-values are plotted on the yaxis.
Appendix Figure S10 . Enrichment plots of the STAT3 gene set for each treatment group versus tumor-bearing control comparisons. Tumor-free control (black checkered), GTx-024-treated tumor-free (blue checkered), GTx-024-treated tumor-bearing (blue), AR-42-treated tumor-bearing (red) and Combination-treated tumor-bearing (green).
6 Appendix Figure S11 . Enrichment plots of the ATF-1 gene set for each treatment group versus tumor-bearing control comparisons. Tumor-free control (black checkered), GTx-024-treated tumor-free (blue checkered), GTx-024-treated tumor-bearing (blue), AR-42-treated tumor-bearing (red) and Combination-treated tumor-bearing (green).
Appendix Figure S12 . A) Genes differentially regulated 4-fold or greater in gastrocnemius muscle by 50 mg/kg AR-42 treatment relative to tumor-bearing vehicle-treated controls from Tseng et al. intersected with genes differentially regulated 2-fold or greater in gastrocnemius muscle by 10 mg/kg AR-42 treatment relative to tumor-bearing controls from Study 1. B) Scatter plot of the 209 overlapping genes identified in (A). C) Canonical pathway analysis using the 147 overlapping genes identified in (A).
Appendix Figure S13 . Standard volcano plot from RNA-seq analyses of Study 1 gastrocnemius muscles showing DEGs for GTx-024-treated tumor-free controls versus vehicle-treated tumor-free controls (colored red). Log2-transformed fold change (FC) in expression is plotted on the x-axis and -log10 transformed Benjamini-Hochburg adjusted p-values are plotted on the y-axis.
Appendix Figure S14.
Overlapping genes among leading-edge subsets from the enrichment analysis of the Ctnnb1 gene set presented in Figure 8 were identified. The comparisons performed were among GTx-024-treated tumor-free mice (GTx-024, Tumor Free; GTx), tumor-bearing mice (Cachexia; Cx) and A) GTx-024-treated tumor-bearing mice (GTx-024, Tumor Bearing; GTB), B) AR-42-treated tumor-bearing mice (AR-42, Tumor bearing; ATB), C) Combination-treated tumor-bearing mice (Combo, Tumor Bearing; CTB). In each case, the directionality of regulation compared to tumor-free controls is designated by arrows.
Appendix Figure S15 . Heat map of DEGs within the Ctnnb1 gene set (mean z score). Tumor-free control (black checkered), GTx-024-treated tumor-free (blue checkered), tumor-bearing control (black), GTx-024-treated tumor-bearing (blue), AR-42-treated tumor-bearing (red) and Combination-treated tumor-bearing (green).
Appendix Tables
Appendix Table S1A- Appendix Table S10 (related to Figure EV2) : p-values from statistical comparisons. One way ANOVA followed by Tukey's multiple comparison test.
A. Luteinizing Hormone (Figure EV2A) B. Spleen Mass ( Figure EV2C ) Appendix Table S11 (related to Figure EV3) : p-values from statistical comparisons. One way ANOVA followed by Tukey's multiple comparison test.
A. Tumor Volume ( Figure EV3A) B. Adipose Mass ( Figure EV3B ) Appendix Table S12 (related to Figure EV4) : p-values from statistical comparisons. One way ANOVA followed by Tukey's multiple comparison test.
A. Tumor Mass (Figure EV4C) B. Terminal Bodyweight (Figure EV4D) C. Gastroc Mass ( Figure EV4E ) Eotaxin: chemokine (C-C motif) ligand 11; G-CSF: granulocyte colony-stimulating factor; GM-CSF: granulocyte macrophage colony-stimulating factor; IFNγ: interferon gamma; IL-1a:
interleukin-1 alpha; IL-1b: interleukin-1 beta; IL-2: interleukin-2; IL-3: interleukin-3; IL-4:
interleukin-4; IL-5: interleukin-5; IL-6: interleukin-6; IL-7: interleukin-7; IL-9: interleukin-9; IL-10:
interleukin-10; IL-12 ( Appendix Table S15 . Post-alignment quality control metrics for RNA-seq dataset. Adaptor sequences were trimmed from reads with Trimmomatic prior to alignment to mm10, and postalignment metrics were calculated with samtools. Bed files used to calculate proportions of genic and exonic reads were obtained from the known Gene 
